San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians
J

New Pharmacological Therapy Guidelines for HFrEF in 2021: Should You Start Treatment with ARNI? Can SGLT2 Inhibitors Eventually Become First Line Therapy?

By San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians FEATURING John Mcmurray
By San Diego Heart Failure Symposium for Primary Care and Internal Medicine Physicians FEATURING John Mcmurray
80 views
February 8, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Related Content

AUTOPLAY
Medical College of Georgia - Augusta University

Cardiovascular Summit at Kiawah 2024

Thu, Jul 18, 2024
11:37
ACC 2022 Conference Coverage

ACC 2022: An Embarrassment of Riches - Updated Guideline Recommendat…

Feat. P. Heidenreich
11:25
ACC 2023 Conference Coverage

ACC 2023: SGLT2i Use - Dos and Don'ts

Feat. A. Armbruster
27:14
MUSC Cardiology

Which Diuretic(s) Are Best in HF? Update Based on Recent Clinical Tr…

Feat. R. Mentz
13:07
Michelle Kittleson

2021 ADA Highlights: Heart Failure With Reduced Ejection Fraction - …

09:52
AHA 2022 Conference Coverage

AHA 2022: Torsemide Comparison With Furosemide for Management of Hea…

Feat. R. Mentz
29:08
Scripps Health

Case Presentation: Complex PCI with IABP

Feat. R. Khedraki, T. Heywood, R. Mohan, A. Srivastava
15:47
Scripps Health

HFpEF in Women

Feat. B. Borlaug
35:16
Scripps Health

HFpEF or Amyloidosis? The Right Therapies for Right Patients

Feat. M. Kittleson
17:08
CVRx | Barostim

Integrating Barostim into a Comprehensive Heart Failure Program ISHL…

Feat. D. Yaranov, P. Patel, R. Gupta, J. Schmitto, E. Chung
17:29
UCLA Health

Cardiac Amyloidosis: A New Era of Diagnostics and Therapeutics

Feat. D. Vucicevic
19:30
ACC 2022 Conference Coverage

Hot Topics in Heart Failure ACC.22

Feat. N. Ibrahim
12:09
ARCH Advanced Revascularization Symposium

End-Stage Heart Failure Therapies

Feat. D. Horstmanshof
14:19
UChicago Medicine

S-QUAD Therapy and Beyond: HFpEF in 2024

Feat. M. Belkin
17:22
Samuel Sherratt

Sotagliflozin, a Dual SGLT 1 and 2 Inhibitor, Has High Membrane Affi…

34:18
Scripps Health

Cancer Survivorship: How To Monitor for Cardiac Disease Following Tr…

Feat. A. Kuo
12:30
Houston Methodist Hospital

Amyloidosis Types and Pathophysiology

Feat. B. Trachtenberg
20:59
Mary E. Money

Digoxin Update 2023: Are the Current Digoxin Monitoring Guidelines H…

84:17
Jefferson Health

2022 Heart Failure Guidelines Review

Feat. D. Haas
27:52
Top Ten Topics in Clinical Cardiology 2023

Medical Management of Diastolic Dysfunction: Does The Emperor Finall…

Feat. S. Pinney
28:48
MUSC Cardiology

Weight Loss as Treatment for HFpEF: An Update on Drugs and Procedures

Feat. S. Litwin